While EPO therapy holds promise, there are challenges to address, including individual variability in treatment response, safety concerns (e.g. thrombosis risk), and the cost and accessibility of this treatment for all SCA patients21. The gene discussed is EPO; the disease is autosomal dominant cerebellar ataxia.